Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.

Molecular oncology - 1 Sept 2018

Bruun Jarle, Sveen Anita, Barros Rita, Eide Peter W, Eilertsen Ina, Kolberg Matthias, Pellinen Teijo, David Leonor, Svindland Aud, Kallioniemi Olli, Guren Marianne G, Nesbakken Arild, Almeida Raquel, Lothe Ragnhild A

Abstract excerpt

We aimed to refine the value of CDX2 as an independent prognostic and predictive biomarker in colorectal cancer (CRC) according to disease stage and chemotherapy sensitivity in preclinical models. CDX2 expression was evaluated in 1045 stage I-IV primary CRCs by gene expression (n = 403) or immunohistochemistry (n = 642) and in relation to 5-year relapse-free survival (RFS), overall survival (OS), and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CDX2 Transcription Factor
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hospitals, University

Share to Microsatellite Instability

Share to Norway

Share to Pharmacogenomic Testing

Share to Proportional Hazards Models

Share to Registries

Source

Open in PubMed Open full text

Identifiers

PMID: 29900672
DOI: 10.1002/1878-0261.12347
PMCID: PMC6120232

Genes

CDX2
BRAF
CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.PMID 29900672Read ↗

The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practiceSemantic proximity Read ↗

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon CancerSemantic proximity Read ↗

Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.Semantic proximity Read ↗

Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal CancerSemantic proximity Read ↗

Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancerSemantic proximity Read ↗

Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancerSemantic proximity Read ↗

CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancerSemantic proximity Read ↗

Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohortsSemantic proximity Read ↗

CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal CarcinomaSemantic proximity Read ↗

Altered expression of CDX2 in colorectal cancersSemantic proximity Read ↗

The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.Semantic proximity Read ↗

Methylation of CDX2 as a Predictor in Poor Clinical Outcome of Patients with Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.